

Safety and Dose Confirmation Period

- N~20
- Up to 14 patients with Primary or secondary wAIHA due to stable autoimmune disorder (Cohort 1)
- Up to 6 patients with secondary wAIHA due to stable lymphoproliferative (Cohort 2)
- Failed one prior wAIHA treatment
- Hemoglobin ≥ 7 to < 10 g/dL

FIG. 1




FIG. 1
CONTINUED